The outcome of gastrointestinal stromal tumors (GISTs) after a surgical resection in our institute

被引:25
作者
Tsukuda, Kazunori
Hirai, Ryuji
Miyake, Takayoshi
Takagi, Shoji
Ikeda, Eiji
Kunitomo, Tadayoshi
Tsuji, Hisashi
机构
[1] Okayama Red Cross Gen Hosp, Dept Surg, Okayama 7008607, Japan
[2] Okayama Red Cross Gen Hosp, Dept Pathol, Okayama 7008607, Japan
关键词
gastrointestinal stromal tumor; risk category; MIB-1; index; MANAGEMENT; DIAGNOSIS; IMATINIB; PROGNOSIS; SURGERY; THERAPY; STOMACH; BIOLOGY;
D O I
10.1007/s00595-007-3535-3
中图分类号
R61 [外科手术学];
学科分类号
摘要
Purpose. Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract arising from Cajal's cells and expressing c-kit. In a consensus report, the clinical behavior of GISTs was categorized into risk classes according to the tumor size and mitotic count. We analyzed the risk categories based on GIST patients who underwent a surgical resection at our institute during a period of 15 years. Methods. We evaluated the risk categories of GISTs and analyzed the outcome and risk categories retrospectively. We presented the MIB-1 score of the tumor instead of mitotic counts for the evaluation of cellular growth because of inaccuracies regarding the mitotic counts. Results. Patients were classified into 4 cases of very low risk, 11 of low risk, 8 of intermediate risk, and 5 of high risk. Four high-risk patients showed recurrence as either liver metastasis or peritoneal dissemination. In addition, local recurrence occurred in one low-risk and one intermediate-risk patient each. Conclusion. Our cases confirmed the correlation between the risk categories and the prognosis. A complete resection with sufficient margin must be confirmed even in low-risk cases to prevent local recurrence. Since high-risk patients showed poor prognosis, the adjuvant treatment with chemotherapeutic regimens must therefore be further studied for high-risk patients.
引用
收藏
页码:953 / 957
页数:5
相关论文
共 20 条
[1]   Prognostic factors after surgery of primary resectable gastrointestinal stroma tumours [J].
Aparicio, T ;
Boige, V ;
Sabourin, JC ;
Crenn, P ;
Ducreux, M ;
Le Cesne, A ;
Bonvalot, S .
EJSO, 2004, 30 (10) :1098-1103
[2]   Consensus meeting for the management of gastrointestinal stromal tumors - Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO [J].
Blay, JY ;
Bonvalot, S ;
Casali, P ;
Choi, H ;
Debiec-Richter, M ;
Dei Tos, AP ;
Emile, JF ;
Gronchi, A ;
Hogendoorn, PCW ;
Joensuu, H ;
Le Cesne, A ;
Mac Clure, J ;
Maurel, J ;
Nupponen, N ;
Ray-Coquard, I ;
Reichardt, P ;
Sciot, R ;
Stroobants, S ;
van Glabbeke, M ;
van Oosterom, A ;
Demetri, GD .
ANNALS OF ONCOLOGY, 2005, 16 (04) :566-578
[3]   Surgery and imatinib in the management of GIST: Emerging approaches to adjuvant and neoadjuvant therapy [J].
Eisenberg, BL ;
Judson, I .
ANNALS OF SURGICAL ONCOLOGY, 2004, 11 (05) :465-475
[4]   Diagnosis of gastrointestinal stromal tumors: A consensus approach [J].
Fletcher, CDM ;
Berman, JJ ;
Corless, C ;
Gorstein, F ;
Lasota, J ;
Longley, BJ ;
Miettinen, M ;
O'Leary, TJ ;
Remotti, H ;
Rubin, BP ;
Shmookler, B ;
Sobin, LH ;
Weiss, SW .
HUMAN PATHOLOGY, 2002, 33 (05) :459-465
[5]   Gastrointestinal stromal tumor: Consistent CD117 immunostaining for diagnosis, and prognostic classification based on tumor size and MIB-1 grade [J].
Hasegawa, T ;
Matsuno, Y ;
Shimoda, T ;
Hirohashi, S .
HUMAN PATHOLOGY, 2002, 33 (06) :669-676
[6]   Gastrointestinal stromal tumours (GIST): biology and treatment [J].
Judson, I .
ANNALS OF ONCOLOGY, 2002, 13 :287-289
[7]   Gastrointestinal stromal tumours (GISTs): a clinicopathological and molecular study of 66 cases [J].
Koay, MHE ;
Goh, YW ;
Iacopetta, B ;
Grieu, F ;
Segal, A ;
Sterrett, GF ;
Platten, M ;
Spagnolo, DV .
PATHOLOGY, 2005, 37 (01) :22-31
[8]   The role of surgery in the management of gastrointestinal stromal tumors (GISTs) in the era of imatinib mesylate effectiveness [J].
Kosmadakis, N ;
Visvardis, EE ;
Kartsaklis, P ;
Tsimara, M ;
Chatziantoniou, A ;
Panopoulos, L ;
Erato, P ;
Capsambelis, P .
SURGICAL ONCOLOGY-OXFORD, 2005, 14 (02) :75-84
[9]   Recent advances in cell biology, diagnosis and therapy of gastrointestinal stromal tumor (GIST) [J].
Logroño, R ;
Jones, DV ;
Faruqi, S ;
Bhutani, MS .
CANCER BIOLOGY & THERAPY, 2004, 3 (03) :251-258
[10]   Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors:: A study by the Spanish Group for Sarcoma Research (GEIS) [J].
Martín, J ;
Poveda, A ;
Llombart-Bosch, A ;
Ramos, R ;
López-Guerrero, JA ;
del Muro, JG ;
Maurel, J ;
Calabuig, S ;
Gutierrez, A ;
de Sande, JLG ;
Martínez, J ;
De Juan, A ;
Laínez, N ;
Losa, F ;
Alija, V ;
Escudero, P ;
Casado, A ;
García, P ;
Blanco, R ;
Buesa, JM .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :6190-6198